IRAK4 degradation in PBMCs of patients with HS and patients with AD treated with KT-474 for 28 d was similar to what was achieved in the HV MAD cohorts treated for 14 d, with an IRAK4 nadir of more than 90% and a similar relationship of plasma KT-474 Ctrough to IRAK4 knockdown (Fig. 2a). This evidence concerns the gene IRAK4 and Alzheimer disease.